أحد الأهداف الرئيسية لـ Life4me + - منع حالات الإصابة الجديدة بفيروس نقص المناعة البشرية والأمراض المنقولة جنسياً الأخرى والتهاب الكبد الوبائي والسل.

يساعد التطبيق على تأسيس اتصال مجهول بين الأطباء والمصابين بفيروس نقص المناعة البشرية. انها تسمح لك بسهولة تنظيم جدول الدواء الخاص بك وإعداد تذكير خفية وشخصية.

إلى الوراء
٢٠ يناير ٢٠١٧, ١٨:٤٤
4468

European Medicines Agency has validated its MAA for new Gilead’s pill for Hepatitis C treatment

European Medicines Agency has validated its MAA for new Gilead’s pill for Hepatitis C treatment - صورة 1

Gilead Sciences, Inc. announced  this Friday that the company’s Marketing Authorization Application (MAA) for the investigational, once-daily, single tablet regimen of sofosbuvir 400 mg, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for the treatment of chronic hepatitis C virus (HCV)-infected patients has been fully validated and is now under assessment by the European Medicines Agency (EMA).

The MAA for SOF/VEL/VOX is supported by data from two Phase 3 studies. The MAA also includes data from two additional phase 3 studies.

Gilead also submitted a New Drug Application to the U.S. Food and Drug Administration for SOF/VEL/VOX on December 8, 2016.

“Direct-acting antiviral treatments have transformed our ability to treat hepatitis C; however, for some patients who have failed to achieve a cure with these regimens, effective and well-tolerated therapies are still needed. The submission of this application reflects our continued commitment to provide treatment options for this life-threatening disease to as many patients as possible, including those who have failed previous direct-acting antiviral therapy, in Europe and around the world,” said Norbert Bischofberger, Ph.D., Executive Vice President of Research and Development and Chief Scientific Officer at Gilead.

مشاركة على وسائل التواصل الاجتماعي